Caribou Biosciences, Inc. (CRBU) AI Stock Analysis

Caribou Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to advancing genome-edited allogeneic cell therapies aimed at treating hematologic malignancies and solid tumors both domestically and internationally. Its portfolio includes CB-010, an allogeneic CAR-T cell therapy targeting CD19 in phase 1 clinical trials for relapsed or refractory B cell non-Hodgkin lymphoma. Other leading candidates include CB-011 targeting BCMA for multiple myeloma, CB-012 targeting CD371 for acute myeloid leukemia, and CB-020, an allogeneic CAR-NK cell therapy for various solid tumors. The company collaborates with AbbVie Manufacturing Management Unlimited Company to accelerate therapy development.

Caribou generated revenue of $11.2M in FY2025, rising 11.7% from $10.0M in FY2024, but down from $34.5M in FY2023. Between FY2020 and FY2025, revenue contracted at a 5-year CAGR of -2.0%. Profitability remained negative, with an FY2025 operating margin of -1220.5% and net income of -$148.1M, following an FY2024 net loss of -$149.1M. Research and development expenses were $109.4M in FY2025. In the trailing twelve months ending June 30, 2026, revenue totaled $10.0M with an operating margin of -1690.4% and an EPS of -$1.08, as quarterly revenue fell 43.8% year-over-year.

As of June 30, 2026, Caribou held $112.3M in cash and short-term investments alongside total debt of $26.7M, yielding net cash of $85.7M. Total assets stood at $142.8M and shareholders' equity was $98.1M, supporting a current ratio of 6.49 and a debt-to-equity ratio of 0.27. In FY2025, operating cash flow was -$111.0M and free cash flow was -$112.4M, with capital expenditures of $1.4M. Over the past five years, the company's share count increased 67.8%.

At a last close price of $0.47 on October 16, 2026, Caribou holds a market capitalization of $50.4M and an enterprise value of $53.2M. The stock trades at a price-to-sales multiple of 5.0x and an EV-to-revenue multiple of 5.3x, compared to a median price-to-sales ratio of 4.1x for its US-listed Healthcare peers. Over the past year, CRBU shares fell 82.4%, lagging the 16.8% return of the S&P 500. Over five years, the stock declined 97.7% compared to an 83.0% gain for the S&P 500.

Wall Street analysts hold 2 Strong Buy and 4 Hold ratings on Caribou, with zero Buy, Sell, or Strong Sell ratings. The mean price target is $5.75, representing an implied premium of 1123.7% over the last close of $0.47. For the fiscal year ending December 31, 2026, analysts estimate revenue of $24.0M and an EPS of -$1.03. Caribou beat EPS estimates in each of the last 4 quarters, and its next earnings report is scheduled for November 11, 2026.

This page is an AI-written research summary of Caribou Biosciences, Inc. (CRBU). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: CRBU income statement, CRBU balance sheet, CRBU key metrics, CRBU analyst forecast, CRBU chart. See the CRBU stock overview for the latest quote and news.